Hugel Aesthetics is moving Letybo sales in-house. The company is standing up a direct US sales force for its botulinum toxin and pairing that infrastructure investment with a new marketing campaign built around K-TOX — its umbrella pitch for Korean-made toxin injectables — as it pushes deeper into the American aesthetics market.

For dermatology and aesthetic practices, the shift is structural, not cosmetic. A direct sales force means the manufacturer's own representatives — not distributors — will be detailing Letybo to injectors, handling account relationships, and executing on the commercial strategy in US clinics.

Who is Hugel, and what is Letybo?

Hugel is a South Korean biopharmaceutical company with a portfolio centered on botulinum toxin and dermal fillers. Letybo is its incobotulinumtoxinA product — a Korean-manufactured neurotoxin that competes in the same category as established US toxin brands.

The company's US arm, Hugel Aesthetics, has now moved from a distribution-oriented model to direct commercial operations for Letybo. That's a common inflection point for foreign manufacturers: once US revenue justifies the overhead, owning the sales channel gives a company control over pricing strategy, prescriber education, and market feedback loops that distributors typically buffer.

What does the K-TOX campaign signal?

Alongside the sales-force buildout, Hugel is launching a K-TOX campaign — a branding play that positions Korean toxin products as a distinct category in the US injector market, on the analogy of K-beauty's earlier foothold in US skincare retail.

The campaign framing matters for positioning. Rather than competing purely on price or clinical interchangeability, K-TOX aims to give prescribers and patients a category identity — Korean aesthetic science — that can be marketed across products and clinics.

The dual move — infrastructure plus consumer-facing brand campaign — suggests Hugel intends to compete for lasting share, not just opportunistic volume.

What does this change for US practices?

The practical question for dermatologists and aesthetic injectors: what does a direct Hugel sales force change at the practice level?

• A dedicated Letybo representative relationship, with manufacturer-backed training and account support rather than third-party distribution contacts.
• A second consumer-facing toxin brand campaign that could drive patient inquiries into clinics that stock K-TOX products.
• Incremental competition in the toxin category, which has historically been dominated by a small number of US-established brands — a dynamic that can affect contracting terms and rebate negotiations for high-volume practices.

Practices that already carry multiple toxins may find the direct model simplifies ordering and support; practices that don't may see renewed detailing activity as Hugel's representatives fan out.

The competitive backdrop

The US botulinum toxin market has been expanding its supplier base in recent years, with several international manufacturers gaining FDA entries and building US commercial operations. Hugel's investment in a direct sales force fits that pattern: foreign toxin makers increasingly treat the US as a primary market requiring dedicated infrastructure, not an export afterthought.

A direct sales force is expensive — representatives, training, territory management — and companies typically commit to it only when they expect sustained prescription volume. The K-TOX campaign, running in parallel, is the demand-side complement: build awareness among patients while the sales force converts prescribers.

What comes next

The rollout's success will show up in prescribing data over the coming quarters — whether direct detailing moves Letybo's US share and whether K-TOX gains traction as a recognized category among patients and injectors.